• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL TRIFECTA¿ GT VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL TRIFECTA¿ GT VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number UNK TRIFECTA GT VALVE
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Atrial Fibrillation (1729); Stroke/CVA (1770); Hemorrhage/Bleeding (1888); Unspecified Infection (1930); Renal Failure (2041); Cognitive Changes (2551)
Event Date 01/01/2017
Event Type  Injury  
Event Description
The article, "surgical aortic valve replacement in octogenarians: single-center perioperative outcomes and 5-years survival", was reviewed.The article presented a retrospective, single center study to evaluate perioperative outcome and long-term survival after surgical aortic valve replacement (savr) in octogenarians, comparing patients with low surgical risk.Devices included in this study were edwards perimount, magna ease, sorin crown, abbott trifecta gt, edwards intuity elite, livanova perceval/perceval plus.The article concluded that savr in patients =80yo is associated with low in-hospital mortality, although a significant proportion of patients develop complications.Long-term follow-up up to 5 years after surgery is acceptable in octogenarians with low surgical risk.[the primary and corresponding author was tiago velho, cardiothoracic surgery department, (b)(6) hospital, (b)(6) portugal, with corresponding email: (b)(6)] the time frame of the study was from january 2017 to january 2021.A total of 195 patients were included in this study, of which 12 (6.2%) received an abbott device.The average age was 82 years and the gender majority was male.Comorbidities included hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, ischemic cardiopathy, atrial fibrillation.
 
Manufacturer Narrative
Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRIFECTA¿ GT VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key18944473
MDR Text Key338186260
Report Number2135147-2024-01254
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodePO
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 03/20/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/20/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK TRIFECTA GT VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/26/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Life Threatening; Disability;
-
-